Results were announced from a phase 3 trial evaluating solriamfetol for major depressive disorder with/without severe excessive daytime sleepiness.

Now, Axsome Therapeutics’ solriamfetol has shown promise in a Phase 3 clinical trial. According to a press release published by the company it demonstrated a 45% reduction in ADHD symptoms compared to ...

Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the treatment of major depressive disorder (MDD) with and without severe excessive ...

Shares of biopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) had declined 6% at 11 a.m. ET today. The slump comes after the company announced the results of a phase 3 trial of solriamfetol ...

Findings showed statistically significant reductions in the ADHD Investigator Symptom Report Scale total score were seen with solriamfetol 150mg vs placebo at week 6. Topline data were announced ...

Using baseline scores as reference points, three measures of cognitive function improved more when patients took solriamfetol vs. placebo. Reported adverse events did not exceed the moderate ...

Solriamfetol did not meet the primary endpoint for MDD but showed benefits in patients with severe EDS. Axsome plans a new Phase 3 trial in 2025 focused on MDD patients with EDS. Wall Street ...

The New York City central nervous system (CNS) specialist has scored in a phase 3 trial testing Sunosi (solriamfetol) on adults with attention deficit hyperactivity disorder (ADHD). The study ...

Axsome Therapeutics, Inc.’s AXSM share price has dipped by 8.23%, which has investors questioning if this is right time to ...

Axsome Therapeutics (AXSM) announced results of the PARADIGM Phase 3 proof-of-concept trial of solriamfetol in major depressive disorder, MDD, with and without severe excessive daytime sleepiness ...

Axsome Therapeutics AXSM announced that the phase III FOCUS study, which evaluated solriamfetol for the treatment of attention deficit hyperactivity disorder (ADHD), has met its primary and key ...